With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …

People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

Abstract In 2011, the European Society for the Study of Tourette Syndrome (ESSTS)
published the first European guidelines for Tourette Syndrome (TS). We now present an …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

Background and Hypothesis The robust evidence base supporting the therapeutic benefit of
ketogenic diets in epilepsy and other neurological conditions suggests this same metabolic …